Trial Profile
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Belzutifan (Primary)
- Indications Haemangioblastoma; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Von Hippel-Lindau disease
- Focus Registrational; Therapeutic Use
- Acronyms LITESPARK-004
- Sponsors Merck Sharp & Dohme Corp.; Peloton Therapeutics
- 21 Oct 2023 According to a Merck & Co Media Release, additional applications are currently under regulatory agency review worldwide based on LITESPARK-004.
- 06 Jun 2023 Results for the subgroup of patients with CNS HBs presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 18 Feb 2023 Results assessing Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan presented at the 2023 Genitourinary Cancers Symposium